Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
ABRAXANE For Metastatic Breast Cancer Approved In Australia
http://www.medicalnewstoday.com/articles/125948.php
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, and Specialised Therapeutics Australia Pty Ltd, today announced that approval has been received from the Therapeutic Goods Administration (TGA) in Australia to market ABRAXANE® (nanoparticle albumin-bound paclitaxel) 100 mg powder for injection (suspension) for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.
----------------------------------------------
** CANCER / ONCOLOGY News **
Start Of Phase 2 Study Of ACE-011 In Patients With Multiple Myeloma
http://www.medicalnewstoday.com/articles/125949.php
Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the initiation of a Phase 2 clinical study of its lead compound ACE-011 in patients with multiple myeloma.
Ardea Biosciences Initiates Phase 1/2 Study Of RDEA119, Its Lead MEK Inhibitor, In Combination With Nexavar® In Patients With Advanced Cancer
http://www.medicalnewstoday.com/articles/125939.php
Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that it has initiated a Phase 1/2 study of RDEA119, its lead mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer, in combination with Nexavar, which is currently approved for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
No news for this category today.
----------------------------------------------
** COLORECTAL CANCER News **
No news for this category today.
----------------------------------------------
** LUNG CANCER News **
No news for this category today.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
Start Of Phase 2 Study Of ACE-011 In Patients With Multiple Myeloma
http://www.medicalnewstoday.com/articles/125949.php
Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the initiation of a Phase 2 clinical study of its lead compound ACE-011 in patients with multiple myeloma.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
No news for this category today.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment